Unknown

Dataset Information

0

AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis.


ABSTRACT: Non-infectious uveitis (NIU) is an intractable, recurrent, and painful disease that is a common cause of vision loss. Available treatments of NIU, such as the use of topical corticosteroids, are non-specific and have serious side effects which limits them to short-term use; however, NIU requires long-term treatment to prevent vision loss. Therefore, a single dose therapeutic that mediates long-term immunosuppression with minimal side effects is desirable. In order to develop an effective long-term therapy for NIU, an adeno-associated virus (AAV) gene therapy approach was used to exploit a natural immune tolerance mechanism induced by the human leukocyte antigen G (HLA-G). To mimic the prevention of NIU, naïve Lewis rats received a single intravitreal injection of AAV particles harboring codon-optimized cDNAs encoding HLA-G1 and HLA-G5 isoforms one week prior to the induction of experimental autoimmune uveitis (EAU). AAV-mediated expression of the HLA-G-1 and -5 transgenes in the targeted ocular tissues following a single intravitreal injection of AAV-HLA-G1/5 significantly decreased clinical and histopathological inflammation scores compared to untreated EAU eyes (p?

SUBMITTER: Crabtree E 

PROVIDER: S-EPMC6934797 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

AAV-mediated expression of HLA-G1/5 reduces severity of experimental autoimmune uveitis.

Crabtree Elizabeth E   Song Liujiang L   Llanga Telmo T   Bower Jacquelyn J JJ   Cullen Megan M   Salmon Jacklyn H JH   Hirsch Matthew L ML   Gilger Brian C BC  

Scientific reports 20191227 1


Non-infectious uveitis (NIU) is an intractable, recurrent, and painful disease that is a common cause of vision loss. Available treatments of NIU, such as the use of topical corticosteroids, are non-specific and have serious side effects which limits them to short-term use; however, NIU requires long-term treatment to prevent vision loss. Therefore, a single dose therapeutic that mediates long-term immunosuppression with minimal side effects is desirable. In order to develop an effective long-te  ...[more]

Similar Datasets

| S-EPMC5640948 | biostudies-literature
| S-EPMC2850934 | biostudies-literature
| S-EPMC7599105 | biostudies-literature
| S-EPMC3392008 | biostudies-other
| S-EPMC3344911 | biostudies-literature
2022-09-10 | GSE213034 | GEO
| S-EPMC8766412 | biostudies-literature
| S-EPMC3369876 | biostudies-literature
| S-EPMC8027130 | biostudies-literature
| S-EPMC4130540 | biostudies-literature